UK AbbVie case augurs single EU medicines market
This article was originally published in Scrip
A victory in the UK Court of Appeal for parallel trader Chemistree against AbbVie could be a step towards a European single market for pharmaceuticals and help reduce drug shortages, said the law firm that represents Chemistree, Matthew Arnold & Baldwin. The case could have important ramifications for EU competition law and how pharma firms manage their supply chains.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.